DARRT-2 Trial Efficacy Phase to Commence

Highlights

- **Safety Steering Committee finds Veyonda® dose safe at 1600 mg**
- **DARRT-2 efficacy phase (Part 2) to begin in late Q1 / early Q2 2023**
- **No further dose escalations planned**

Sydney 17 January 2023: Innovative Australian biotech **Noxopharm Limited (ASX:NOX)** announces the DARRT-2 Safety Steering Committee has reviewed safety data from the third cohort of patients from the dose escalation part of the DARRT-2 trial.

The DARRT-2 Phase 2 trial is evaluating Noxopharm's clinical drug candidate Veyonda® in combination with low-dose external beam radiotherapy with a focus on the treatment of prostate cancer.

The third cohort of patients was treated with a 1600 mg dose, which was found to be safe. This means that no further dose escalations will occur and the trial can soon progress into Part 2, which will evaluate efficacy signals while safety data continues to be collected. Pending some protocol requirements, Part 2 is expected to begin in late Q1 or early Q2 this year.

Noxopharm CEO Dr Gisela Mautner said: "This meeting marks a positive development in the progress of DARRT-2. We are proceeding according to schedule as we now wind down the first part of the trial and look to start focusing on efficacy in the very near future.

"As stated in the recent AGM, we are actively exploring ways to reduce patient numbers and costs while bringing forward efficacy data. And when results are meaningful, we will target data releases via high-profile conferences and peer-reviewed publications to maximise commercial potential."

-ENDS-

About DARRT

DARRT is a Phase 1b/2a dose expansion, dose escalation clinical trial in patients with metastatic cancers across multiple sites in the US, Europe and Australia. The trial is examining the combination of Veyonda with low-dose radiotherapy for the treatment of prostate cancer as the major focus, and also including breast and lung cancer patients on an exploratory basis.

Veyonda is combined with the application of low-dose (up to 25 Gy) external beam radiotherapy in 1-5 fractionated doses to a single tumour in a single treatment cycle. Veyonda is administered daily for up to 14 days in conjunction with the single radiotherapy cycle, and then in repeated monthly cycles without radiotherapy.

Data generated to date in the DARRT-1 trial has shown a good safety profile and encouraging efficacy signals with good tumour control and improvements in relevant biochemical markers and

reduced pain in patients with advanced metastatic prostate cancer. DARRT-2 builds on the encouraging safety and efficacy data from DARRT-1 and expands into higher doses of Veyonda, repeat cycles of Veyonda, and three different cancer types (prostate, breast, lung).

Endpoints will be safety and tolerability, as well as clinical measures of efficacy such as tumour size changes, time until disease progression, health-related quality of life measurements, and overall survival.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its lead clinical-stage drug candidate Veyonda®, plus two innovative technology platforms Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.